Our products reach 100 countries; 80% of our revenue is derived from export, 20% from our domestic market. Owing to the well-coordinated operations of our sites in Hungary, our extensive network of external markets, and our subsidiaries and offices operating in 17 countries, we are able to contribute to the treatment of more than 30 million patients. Our most important markets are the Central Eastern European region, Russia, and the Commonwealth of Independent States.

In 18 of these countries our products are available under Egis’ brand names through our network, subsidiaries and representative offices. In these countries more than 30 million patients have been treated with Egis medicines yearly.
The company’s presence focuses on Hungary, Russia, CEE and CIS countries and Vietnam.
4600 employees work for Egis Group’ s success: almost 3400 employees in Hungary and over 1200 employees at the subsidiaries and representative offices of Egis Group.

Since the establishment of the company more than 110 years ago, we have become one of the most significant operators in the Hungarian pharmaceutical market. Based on the number of boxes sold, we have been one of the top 3 suppliers in Hungary.

Egis Group’s product portfolio comprises 653 products. In the 2022/2023 financial year, we distributed medicines of 177 product lines — comprising 158 different active ingredients. Although our main therapeutic areas are the cardiovascular and central nervous system diseases, we also provide modern treatment solutions in the fields of  diabetology, dermatology and wound care.